Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. · ¶27
Given these standards, Amarin misses the mark in arguing that it need not do more than “allege . . . a plausible chain of events through which statements made by [Hikma] could lead a healthcare provider . . . to prescribe or dispense Hikma’s drug to reduce a patient’s cardiovascular risk.” Brief for Respondents 21 (alterations and internal quotation marks omitted). Amarin relies primarily on two cases to press its point. First, it points to our holding in National Rifle Association of America v. Vullo, 602 U. S. 175 (2024), that, “[t]o state a claim that the government violated the First Amendment through coercion of a third party, a plaintiff must plausibly allege conduct that, viewed in context, could be reasonably understood to convey a threat of adverse government action,” id., at 191 (emphasis added). Importing this First Amendment standard into the induced-infringement context,…Read in context ›
slip opinion
Source edition
Passage preview. Read in context for the complete text, notes and references.